Compare NTLA & NSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | NSP |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United States | United States |
| Employees | N/A | 4200 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2016 | 1996 |
| Metric | NTLA | NSP |
|---|---|---|
| Price | $11.77 | $47.89 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 3 |
| Target Price | $20.02 | ★ $47.67 |
| AVG Volume (30 Days) | ★ 3.5M | 319.1K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.45% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ 0.97 |
| Revenue | $67,671,000.00 | ★ $6,812,000,000.00 |
| Revenue This Year | N/A | $3.45 |
| Revenue Next Year | $62.75 | $6.95 |
| P/E Ratio | ★ N/A | $49.38 |
| Revenue Growth | ★ 16.92 | 3.51 |
| 52 Week Low | $7.95 | $18.57 |
| 52 Week High | $28.24 | $55.90 |
| Indicator | NTLA | NSP |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 37.45 |
| Support Level | $11.51 | $37.61 |
| Resistance Level | $13.88 | $48.14 |
| Average True Range (ATR) | 0.60 | 1.97 |
| MACD | -0.01 | -0.40 |
| Stochastic Oscillator | 33.13 | 16.21 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.